Penumbra, Inc. reported significant financial performance in its latest 10-Q filing for the second quarter of 2026, with total revenue reaching $390.0 million, a 14.9% increase from $339.5 million in the same period last year. For the first half of 2026, revenue totaled $764.8 million, up 15.3% from $663.6 million in the first half of 2025. The company’s gross profit for the second quarter was $264.9 million, reflecting a gross margin of 67.9%, compared to 66.0% in the prior year. However, net income for the quarter decreased to $34.8 million, down from $45.3 million in Q2 2025, resulting in diluted earnings per share of $0.88, compared to $1.15 a year earlier.
The company experienced notable changes in its operating expenses, which rose to $223.9 million in the second quarter, up from $183.2 million in the same quarter of 2025. This increase was primarily driven by a 24.1% rise in sales, general, and administrative expenses, attributed to higher personnel costs and acquisition-related expenses linked to the pending merger with Boston Scientific Corporation. Research and development expenses also increased by 9.4% to $25.4 million, reflecting ongoing investments in product development.
Penumbra's strategic developments include the announcement of a merger agreement with Boston Scientific, which values the company at approximately $14.5 billion. Under the terms of the agreement, shareholders can choose to receive $374 in cash or shares of Boston Scientific stock. The merger is expected to close by the end of 2026, pending regulatory approvals. Additionally, the company is expanding its manufacturing capabilities with a new facility in Costa Rica, which is projected to cost around $88 million.
Operationally, Penumbra reported a strong performance in its thrombectomy and embolization product lines, with thrombectomy sales increasing by 12.5% and embolization and access products by 20.0% in the second quarter. The company’s international sales accounted for 21.7% of total revenue, with a 7.6% increase in international sales compared to the previous year. As of June 30, 2026, Penumbra had $205.3 million in cash and cash equivalents and $453.5 million in marketable investments, indicating a solid liquidity position.
Looking ahead, Penumbra anticipates continued growth driven by its expanding product portfolio and market penetration. However, the company acknowledges potential challenges, including competition, regulatory hurdles, and fluctuations in foreign currency exchange rates. The management remains optimistic about the future, emphasizing the importance of ongoing product innovation and strategic investments to enhance operational efficiency and market share.
About Penumbra Inc
Penumbra, Inc. develops innovative medical devices for treating vascular and neurovascular conditions, including thrombectomy, embolization, and access products. Its portfolio targets stroke, pulmonary embolism, aneurysms, and other blood vessel disorders, primarily serving healthcare providers worldwide. The company emphasizes proprietary technology, regulatory compliance, and clinical research to deliver safe, effective, and cost-efficient solutions in endovascular therapy.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov